Provided are methods for producing a population of cells enriched with non-activated/non-mature cells, in particular non-activated/non-mature T and/or B cells, optionally genetically modified T and/or B cells. The method includes contacting a heterogeneous population of mammalian cells with an apoptosis inducing ligand, wherein said contacting induces apoptosis of active/mature cells while non active/mature cells remain resistant to the apoptotic signal. Further provided are therapeutic uses of the enriched cell populations.

The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of UCB and other transplant grafts, thereby significantly improving patient outcomes.

There is described herein methods for improving tumor infiltrating lymphocyte (TIL) therapy by limiting the effect of innate lymphoid cells (ILCs) thereon. For example, in an aspect, there is provided a method of treating cancer in a patient in need thereof, comprising inhibiting the suppressive effect of CD56.sup.+CD3.sup.− innate lymphoid cells (ILCs) on tumor infiltrating lymphocyte (TIL) propagation or expansion.

The present invention relates to methods for the specific separation of target cells from a biological sample, comprising specific binding of the target cells to phase-change hydrogel compositions and separation of respective cell-hydrogel complexes by counter-current centrifugation.

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

Provided herein are methods for the isolation of platelets, for example, isolation of platelets from umbilical cord blood. In certain embodiments, presented herein are methods for preparation of platelet rich plasma. In one aspect, provided herein are methods for isolation of platelets from blood. In certain embodiments, presented herein are methods for isolation of platelets from cord blood, e.g., human cord blood. The isolated platelets can be used for a variety of applications, including, for example, methods of wound healing, organ repair and/or regeneration, and/or tissue repair and/or regeneration, in either autologous or allogeneic settings.

The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem/progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional αβ-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.

A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

Methods for directly measuring a patient's relative sensitivity to radiation therapy are provided. In particular, the methods provide for calculating a radiation sensitivity quotient for monocytes in culture. The methods can be incorporated into radiotherapy (RT) treatment planning systems, which are also provided. The methods can be used to optimize patient treatment plans, thereby developing patient-specific radiation treatment plans. Methods for treating a patient with radiotherapy with an optimized treatment plan are provided.